Dyax Corp. (Nasdaq: DYAX) announced that the Food and Drug Administration approved its hereditary angioedema treatment Kalbitor sending shares of the biopharmaceutical soaring 74 cents to $4.24.
FDA Approves Dyax's Kalbitor
December 02, 2009 at 12:28 PM EST
